BridgeBio Pharma, Inc. (BBIO) shares fell 1.1% to $65.57 as of September 28, 2026, a modest decline from the prior close of $66.28. BestStocks flagged the session as a major change for BBIO. Below, we break down what changed for BBIO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
BBIO fell 1.1% to $65.57
BBIO fell 1.1% in its latest session, moving from $66.28 to $65.57.
ValuationWeak confidence
Rel. volume
0.7×
Below Avg
Vs peers
—
No comparable peers
Market cap
$12.8B
NASDAQ Global Select
Analyst target
$110
+67.9% vs price
Price chart
Aug 28 – Sep 25
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for BridgeBio Pharma, Inc. investors
For BridgeBio Pharma, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Negative session, down 1.1%. Wall Street's consensus price target sits at $110.09, implying +67.9% upside from $65.57. BestStocks rates the overall signal quality weak (36/100). With earnings roughly 30 days out, the next report is the most likely near-term test of the move.
BBIO price reaction
BBIO last traded at $65.57, down $0.71 (-1.07%) from the previous close of $66.28. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $65.57 and $76.60, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on BridgeBio Pharma, Inc. (BBIO)
The consensus analyst price target on BridgeBio Pharma, Inc. (BBIO) is $110.09, 67.9% above the recent $65.57. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BBIO line up.
▲ The bullish case
+Wall Street's consensus price target of $110.09 implies +67.9% upside from $65.57.
+The Street's most bullish target is $130.00 (+98.3%).
+Positive price momentum.
▼ The bearish case
−Material negative event.
−Negative session, down 1.1%.
−BridgeBio shares fell 5.68% to $68.27 on a combination of profit-taking, secondary selling pressure from KKR and insider sales, and broader biotech sector weakness, according to the web_catalyst synthesis.
−BridgeBio Pharma shares declined 2.40% to $76.80 as investors digest a secondary common stock offering by major shareholder KKR Genetic Disorder L.P., which increases near-term share supply.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 27, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
BBIO moved +3.48% from its $66.90 open to a $69.23 close on 2026-09-22.
Material / Earnings2026-09-17-1.4%
BridgeBio Pharma, Inc. (BBIO) moved −3.60% from $69.83 to $67.31 on 2026-09-17, reaching a new 30-day low. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
BridgeBio shares fell 5.68% to $68.27 on a combination of profit-taking, secondary selling pressure from KKR and insider sales, and broader biotech sector weakness, according to the web_catalyst synthesis. Volume was elevated at 1.85x the time-adjusted average, consistent with active institutional repositioning.
BridgeBio Pharma fell 4.71% to $72.50 on investor caution over rising operating costs and downward earnings revisions following Q2 results that showed wider-than-expected losses tied to spending on drug commercialization including Attruby, per Zacks and Yahoo Finance. Profit-taking also pressured the stock after a strong summer rally, compounded by a mid-August secondary offering that increased share float.
Material / Earnings2026-09-09+1.8%
BridgeBio Pharma, Inc. (BBIO) moved +3.33% from $73.63 to $76.08 on 2026-09-09. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, modestly elevated.
BridgeBio Pharma shares declined 2.40% to $76.80 as investors digest a secondary common stock offering by major shareholder KKR Genetic Disorder L.P., which increases near-term share supply. The move follows a multi-month rally that has left the stock trading at a steep valuation multiple relative to the broader biotech sector, prompting profit-taking despite strong Q2 2026 results and surging Attruby drug sales. Volume of 938,918 shares is tracking at 0.88x the historical average for this point in the session.
Material / Earnings2026-08-18+3.9%
BridgeBio Pharma, Inc. (BBIO) moved +3.38% from $80.27 to $82.98 on 2026-08-18. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
BridgeBio Pharma declined 1.56% to $79.94 on elevated volume (2.10x intraday average), amid references to a Q2 earnings miss on revenue guidance cited by finance.yahoo.com and investing.com. The move reflects investor reaction to the company's second-quarter results released on 2026-08-14.
In-depth BBIO event analyses
Permanent, dated analyses of BBIO's most significant sessions.
BBIO fell 1.1% to $65.57. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did BBIO stock fall?
BBIO lost 1.07% ($0.71) versus the prior close of $66.28, last trading at $65.57 on 0.7× average volume.
When is BridgeBio Pharma, Inc.'s next earnings date?
BBIO's next earnings report is estimated for 2026-10-28 — about 30 days away.
What is the analyst price target for BBIO?
The consensus analyst price target for BBIO is $110.09, about 67.9% above the current $65.57. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks BBIO
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BBIO-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for BBIO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 28, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
